We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
-2.97%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$107B
AUM Growth
-$4.88B
Cap. Flow
+$802M
Cap. Flow %
0.75%
Top 10 Hldgs %
28.03%
Holding
4,262
New
46
Increased
1,724
Reduced
2,093
Closed
87

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$78.7M
2
XYZ
Block Inc
XYZ
+$49.3M
3
V icon
Visa
V
+$46.1M
4
AAPL icon
Apple
AAPL
+$45.4M
5
DASH icon
DoorDash
DASH
+$45.1M

Sector Composition

Rank Sector Weight
1 Technology 28.67%
2 Financials 14.43%
3 Healthcare 10.97%
4 Consumer Discretionary 10.82%
5 Industrials 8.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FCEL icon
3001
FuelCell Energy
FCEL
$1.63B
$147K ﹤0.01%
32,012
+5,585
+21% +$41.6K
TSQ icon
3002
Townsquare Media
TSQ
$118M
$147K ﹤0.01%
18,036
+3,393
+23% +$29.5K
KOD icon
3003
Kodiak Sciences
KOD
$2.84B
$147K ﹤0.01%
52,274
+805
+2% +$4.38K
STRS icon
3004
Stratus Properties
STRS
$154M
$146K ﹤0.01%
8,245
-21
-0.3% -$398
EDU icon
3005
New Oriental
EDU
$8.98B
$146K ﹤0.01%
3,054
-1,810
-37% -$93K
SLDB icon
3006
Solid Biosciences
SLDB
$900M
$146K ﹤0.01%
39,422
-4,255
-10% -$18.2K
EGAN icon
3007
eGain
EGAN
$201M
$145K ﹤0.01%
29,950
+1,266
+4% +$7.17K
LNKB
3008
DELISTED
LINKBANCORP
LNKB
$145K ﹤0.01%
21,424
-1,377
-6% -$9.9K
BRCC icon
3009
BRC Inc
BRCC
$250M
$144K ﹤0.01%
69,066
+2,317
+3% +$5.9K
ADVM
3010
DELISTED
Adverum Biotechnologies
ADVM
$144K ﹤0.01%
32,999
+1,332
+4% +$6K
RAPP
3011
Rapport Therapeutics
RAPP
$2.18B
$144K ﹤0.01%
14,358
+4,109
+40% +$53.3K
NKTX icon
3012
Nkarta
NKTX
$172M
$144K ﹤0.01%
78,185
-3,006
-4% -$6.16K
EDIT icon
3013
Editas Medicine
EDIT
$442M
$144K ﹤0.01%
123,850
-16,867
-12% -$24.8K
ALEC icon
3014
Alector
ALEC
$199M
$143K ﹤0.01%
116,635
+740
+0.6% +$1.21K
CCCC icon
3015
C4 Therapeutics
CCCC
$412M
$143K ﹤0.01%
89,633
-10,382
-10% -$31K
SNDA icon
3016
Sonida Senior Living
SNDA
$1.91B
$143K ﹤0.01%
6,125
+1,681
+38% +$39.8K
ATLO icon
3017
AMES National
ATLO
$277M
$142K ﹤0.01%
8,112
-754
-9% -$13.5K
LRMR icon
3018
Larimar Therapeutics
LRMR
$432M
$140K ﹤0.01%
65,018
+8,818
+16% +$27.9K
CRTO icon
3019
Criteo S.A. Ordinary Shares
CRTO
$923M
$138K ﹤0.01%
3,908
-226
-5% -$8.78K
OBIO icon
3020
Orchestra BioMed
OBIO
$254M
$135K ﹤0.01%
31,657
+914
+3% +$4.54K
GENC icon
3021
Gencor Industries
GENC
$212M
$135K ﹤0.01%
11,140
-1,501
-12% -$21.3K
SCPH
3022
DELISTED
scPharmaceuticals
SCPH
$135K ﹤0.01%
51,499
+8,945
+21% +$29.1K
SEPN
3023
Septerna Inc
SEPN
$1.75B
$135K ﹤0.01%
23,318
+3,323
+17% +$37.9K
ZNTL icon
3024
Zentalis Pharmaceuticals
ZNTL
$302M
$134K ﹤0.01%
84,542
-7,672
-8% -$16.5K
SMID icon
3025
Smith-Midland
SMID
$152M
$133K ﹤0.01%
4,265
+372
+10% +$13.7K

Similar funds

RhumbLine Advisers's Q1 2025 Portfolio in Review

As of Q1 2025, RhumbLine Advisers held 4,262 positions worth $107B, down 4.4% from $112B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Trading was light in Q1 2025: portfolio turnover was 3.1%. RhumbLine Advisers opened 46 new positions and exited 87, leaving the 4,262-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 29% of assets, down from 31% a quarter earlier, followed by Financials and Healthcare.

  • RhumbLine Advisers's largest Q1 2025 buy was Block Inc: 660,293 shares worth $35.9M.
  • RhumbLine Advisers added most to iShares Russell 2000 ETF in Q1 2025, an estimated $78.7M increase.
  • RhumbLine Advisers's biggest Q1 2025 reduction was Meta Platforms (Facebook), cutting an estimated $78.8M.
  • RhumbLine Advisers fully exited Aspen Technology Inc in Q1 2025, selling an estimated $19.7M.
  • RhumbLine Advisers's ten largest holdings make up 28% of its $107B portfolio in Q1 2025.
  • RhumbLine Advisers opened 46 new positions and closed 87 in Q1 2025.
  • RhumbLine Advisers's portfolio value fell 4.4% quarter-over-quarter to $107B.

Based on RhumbLine Advisers's 13F filing for Q1 2025, filed 8 Apr 2025.